For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

SWOG S1706

Trial Overview

Official Title

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Purpose

To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning.

Diagnosis

Breast cancer patients who have had surgery and whose cancer is diagnosed as inflammatory.

Eligibility

Must have completed chemotherapy before mastectomy, as well as the mastectomy, itself.

They may or may not have had chemotherapy after surgery.

Must be registered to the study at least 3 weeks, but no more than 12 weeks after mastectomy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Olaparib (Lynparza┬«)
  • Radiation Therapy
  • Lab Biomarker Analysis
  • ARM I: Olaparib 25mg BID + Standard Radiation Therapy
  • ARM II: Radiation Therapy Alone

Patients will be followed every 3 months from start of study for the first 3 years, and then every 6 months until 8 years from start of study.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Marker Status
All ER/PR/Her2 statuses are accepted
Phase
Phase II
Methodist Health System Trial Code
S1706
Related Specialties